Table 1:

Case Example Comparison of Two Landmark National Diabetes Prevention Trials

Original Diabetes prevention Study	Study Eligibility	Study Intensity & Duration	Translational Outcomes	National Program	Program Eligibility	Program Intensity & Duration
US Diabetes Prevention Program1	Age ≥ 25 years BMI ≥24 kg/m2 (Asian ≥22 kg/m2 ) FPG: 95–125 mg/dL OGTT: 140–199 mg/dL	• ≥16 1:1 sessions 0–6 months followed by ≥6 sessions/7–12 mo (≥22 hours/1 year) • Voluntary supervised activity ≥2 times per week	• Average one year weight loss among participants in YMCA DPP was 5.6%3 • In a pooled meta-analysis of programs based on US-DPP, mean weight loss was −3.77 kg, mean HbA1c reduction of −0.21% with an average follow-up of 9.3 months4	CDC NDPP (US)6	Age ≥ 18 years + BMI ≥25 kg/m2 (Asian ≥23 kg/m2 ) + HbA1c 5.7–6.4% (39–46 mmol/mol) OR FPG: 100–125 mg/dL OR OGTT: 140–199 mg/dL OR past GDM OR CDC/ADA Prediabetes Risk Testa >5	• ≥16 sessions in months 1–6; ≥6 sessions in months 7–12 (≥22 hours) • Medicare (MDPP) two year program extends monthly sessions • >780 program providers CDC-certifiedb
Finnish Diabetes Prevention Study2	Age 40–64 years BMI ≥25 kg/m2 Mean value of two OGTT: 140–199 mg/dL	• 7 1:1 sessions at weeks 0, 1, 5, 12, 16, 24 and 36 then every 3 months for remaining 2 years (≥ 16 sessions/3 years) • Voluntary supervised activity offered	>17% of participants in Finnish national translation project achieved ≥5% weight loss5	NHS DPP (UK)7	Age ≥ 18 years Hba1c: 6.0–6.4% (42–46 mmol/mol) FPG: 110–125 mg/dL (5.5–6.9 mmol/L)	≥13 sessions over ≥ 9 months (≥16 hours) • four program providers NHS-certified
				FIN-D2D (Finland)8	Age ≥ 18 years FINDRISCc ≥ 15	• 4–8 sessions every 1–2 weeks + 1 follow-up session
				Life! (Australia)9	Age ≥ 50 years AUSDRISKc ≥12 (Age ≥ 18 years if Aboriginal and Torres Strait Islander descent and/or history of GDM, CVD)	• 5 sessions every 2 weeks + 1 follow-up session at 8 months • provider network of nonprofit, public sector, and private agencies

FPG: Fasting Plasma Glucose

OGTT: Oral Glucose Tolerance Test

BMI: Body Mass Index

GDM: Gestational Diabetes Mellitus

CVD: Cardiovascular Disease

^aOrganizations must meet minimum 35% of cohort entering with qualifying blood test or history of gestational diabetes. Medicare DPP requires serum-based testing. CDC/ADA Prediabetes Risk Test is a risk tool comprimised of scored questions to estimate probaiblity of developing T2D.

^bFully recognized by the CDC Diabetes Prevention Recognition Program

^cFINDRISC (8 questions) and AUSDRISK (10 questions) are risk tools comprised of scored questions, with the total test score providing a measure of the probability of developing T2D.